Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Periciazine is a phenothiazine with a piperidine side chain. It has similar antipsychotic action to other phenothiazines but produces more sedation.”
“A peak concentration of 150 ng/ml (410 nmol/l) was achieved 2 hours after drug administration and the half-life was approximately 12 hours.”
“Some phenothiazines are moderate inhibitors of CYP2D6. There is a possible pharmacokinetic interaction between inhibitors of CYP2D6, such as phenothiazines, and CYP2D6 substrates.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Pericyazine (Periciazine) — Clinical Summary for Prescribers
Positioning Pericyazine is a piperidine phenothiazine (S4) indicated for severe anxiety and tension states and maintenance treatment of psychosis. It is distinguished from other phenothiazines by more pronounced sedation, which may be therapeutic or problematic depending on clinical context.
Key Prescriber Considerations
Sedation and psychomotor effects are predictable and often limiting. Drowsiness typically attenuates within days, but impaired psychomotor activity is a frequent initial reaction. Counsel patients regarding driving and operating machinery until effects are established.
Cardiovascular risk requires baseline and ongoing vigilance. Orthostatic hypotension is common; serious cardiac arrhythmias (including torsade de pointes, ventricular tachycardia/fibrillation) have been reported, possibly dose-related. Assess cardiac risk before initiation and monitor during therapy.
Extrapyramidal symptoms are common and age-dependent. Acute dystonias/dyskinesias predominate in children and young adults (typically within first 4 days or after dose increases); parkinsonism is more common in adults and the elderly. Akathisia may occur.
Haematological monitoring is essential given reports of agranulocytosis, leukopenia, eosinophilia, and thrombocytopenia. A previous history of blood dyscrasias or agranulocytosis is an absolute contraindication. Instruct patients to report fever, sore throat, or unusual bruising promptly.
Hepatic effects: Jaundice occurs rarely; withhold treatment if it develops.
Venous thromboembolism (including fatal pulmonary embolism) has been reported with antipsychotics. Assess VTE risk factors.
Toxic-confusional states warrant immediate cessation.
Contraindications (Absolute) - Circulatory collapse; acute intoxication with CNS depressants/coma - Previous blood dyscrasias or agranulocytosis - Hypersensitivity to periciazine, phenothiazines, or excipients (including wheat starch/gluten) - Angle-closure glaucoma; urinary retention from urethroprostatic disorders - Concomitant spinal/regional anaesthesia - Uncontrolled convulsive disorders - Children <1 year (SIDS association) - Combination with dopaminergic antiparkinsonism agents - Phaeochromocytoma or liver dysfunction (avoid neuroleptics)
Practical Points - Half-life ~12 hours; peak concentration ~2 hours post-dose - Moderate CYP2D6 inhibitor — assess for interactions with CYP2D6 substrates - Review concomitant medications for additive CNS depression, QT prolongation, and anticholinergic burden
---
Bottom line: Pericyazine is effective for its indications but demands proactive screening for haematological, cardiac, and neurological adverse effects, with particular caution in the elderly and those with relevant comorbidities.